- 1 The central response of electroacupuncture for anxiety in
- 2 people with obesity based on resting-state functional
- magnetic resonance imaging: a protocol for a randomized,
- 4 blinded, sham-controlled trial
- 5 Qi Shu<sup>1,2+</sup>, Qiumei Peng<sup>2,3+</sup>, Wenxiu Duan<sup>1,2</sup>, Fan Zhang<sup>1,2</sup>, Qing Yu<sup>2,3</sup>\* and Ronglin
- 6 Cai<sup>2,3,4</sup>\*
- 8 \* Correspondence: yuqingtcm@126.com; ronglincai@ahtcm.edu.cn
- 9 <sup>1</sup> College of Chinese Medicine, Anhui University of Chinese Medicine, 350 Longzihu Road, Hefei,
- 10 China
- <sup>2</sup> Anhui Province Key Laboratory of Meridian Viscera Correlationship, 103 Meishan Road, Hefei,
- 12 China.
- <sup>3</sup> Institute of Acupuncture and Meridian Research, Anhui University of Chinese Medicine, 350
- 14 Longzihu Road, Hefei, China.
- <sup>4</sup> Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine, Insitute of
- 16 Health and Medicine, Hefei Comprehensive National Science Center, 103 Meishan Road, Hefei,
- 17 China.
- 18 **Introduction** Obesity is a problem that is increasing worldwide and anxiety is a major
- 19 psychological disorder associated with obesity. Electroacupuncture (EA) has been
- 20 proved to be a feasible treatment for obesity and anxiety respectively in clinical
- 21 practice. However, to date, there are no data on EA's effectiveness on anxiety for
- 22 people with obesity. Therefore, this study aims to evaluate the efficacy and safety of
- 23 EA for anxiety in people with obesity, and to observe the brain functional status of
- 24 patients and the intervention effects of EA on brain function by functional magnetic
- resonance imaging (fMRI).
- 26 Methods and analysis This study is a randomized, blinded, sham-controlled and
- 27 clinical trial. 72 obesity patients from two hospitals with anxiety will be randomly
- 28 divided into EA group and control group in 1:1 ratio by using a random number table.
- 29 Patients in EA group will receive EA treatment at specific acupoints with penetrating
- 30 needling for 8 weeks. The control group will receive Park's acupuncture with non-
- 31 penetrating needling. Weight, waist, BMI (Body Mass Index), SAS (Self-rating
- 32 Anxiety Scale), STAI (State-Trait Anxiety Inventory) and PSQI (Pittsburgh Sleep
- 33 Quality Index) will be performed before, after 8-week treatments and at one-month
- 34 follow-up in patients. Objective metabolic parameters such as triglyceride, total
- 35 cholesterol, fasting blood glucose, ghrelin, leptin, cortisol and adrenocorticotropic
- 36 hormone will also be detected before and after 8-week intervention. 20 patients will
- 37 be randomly selected from EA group and control group, respectively, before
- 38 treatment, and 20 paired healthy participants will be recruited at the same time. The
- 39 20 patients will be scanned by fMRI before and after treatment while the other 20
- 40 healthy participants will be scanned only at baseline. Regional homogeneity,
- 41 amplitude of low-frequency fluctuation and resting-state-functional-connectivity will

- 42 be carried out to compare the dysfunctional brain regions between patients and
- 43 healthy participants, as well as the differences between two groups of patients after
- 44 treatment.
- 45 Ethics and dissemination The study protocol has been approved by the Hospital
- 46 Ethics Committee of Second Affiliated Hospital of Anhui University of Chinese
- 47 Medicine (2023-zj-42). Informed consent will be obtained prior to starting study-
- 48 ralated procedures. The results will be disseminated in peer-reviewed journals and at
- 49 scientific conferences.
- 50 Trail Registration number Chinese Clinical Trail Registry. ChiCTR2400083594,
- 51 registered 29 April 2024.
- 52 Keywords: Electro-acupuncture, Obesity, Anxiety, Randomized controlled trial
- 53 Word count: 3816.

#### 54 Introduction

- 55 Overweight/obesity is a global issue with detrimental health impacts, which increases
- 56 the incidence of type 2 diabetes, fatty liver, coronary heart disease, and anxiety or
- 57 depression related mental disorders [1,2]. It is reported that more than 2.0 billion
- 58 adults worldwide are overweight [3]. In China, approximately 11.1% children and
- 59 adolescents aged 6-17 years are overweight and 7.9% are obese [4]. In addition,
- 60 psychological factors often co-occur with obesity and may consequently maintain
- 61 obesity [5,6]. For instance, high level of stress from work may change eating patterns
- 62 and lead to excessive food intake toward a higher fat and sugar diet [7]. People with
- 63 obesity and a disposition to anxiety, exhibit more emotional eating than normal
- 64 weight people in an experimental setting. Similarly, the stigmatization of body weight
- 65 and social discrimination may aggravate the anxiety and depression of obese
- 66 individuals [8]. Anti-obesity medications or bariatric surgery may assist people in
- 67 reaching and sustaining sufficient weight loss to meet treatment goal, but the 68 accompanying adverse gastrointestinal effects and adverse neuropsychiatric effects
- 69 such as irritability and insomnia add suffering to their lives. Although the relationship
- 70 between obesity and psychological disorders is complex, studies have shown that 71
- anxiety is a common comorbidity associated with eating and weight-related disorders
- 72 [9,10]. Therefore, psychological intervention has also been introduced in the
- 73 multimodal management of patients with obesity.

### Rationale

- 75 Overweight/obesity constitutes a global health priority because of its prevalence and
- 76 its association with numerous complications, among which anxiety is an undeniable
- 77 one. People with obesity report more emotional eating than normal-weight individuals,
- 78 and especially more emotional eating that is triggered by negative emotions, including
- 79 anxiety and depression [11,12]. In addition, individuals who are exposed to stress for
- 80 a long time may activate the hypothalamic-pituitary-adrenal (HPA) axis, leading to
- 81 binge eating and a preference for high sugar and high-fat foods, resulting in
- 82 overweight/obesity [13-15]. Therefore, management of overweight/obesity requires
- 83 multidisciplinary treatment and a long-term care, making it a tough work.

Social demand for an effective and safe treatment of obesity, including complementary and alternative medicine has increased, and acupuncture therapy may be a promising and acceptable treatment for overweight/obesity [16]. Currently, accumulating evidences have been shown in the clinical studies and meta-analyses in terms of the effectiveness and safety of electroacupuncture treatment for weight loss [17-20]. Researchers have identified that acupuncture can adjust various metabolic functions [21], improve the fat decomposition and suppress food addiction to achieve weight loss [22]. Specially, lifestyle modification plus acupuncture treatment is more effective than lifestyle modification alone [23]. According to previous research, acupuncture combined with diet or exercise may be the most effective intervention for weight loss [24]. Diet diary, a mild diet intervention (non low-carbon diet), is used to improve the compliance of participants, and also facilitates our observation so as to eliminate the interference of diet on EA treatment. Furthermore, other evidence suggests that acupuncture exerts effect on the neuroendocrine system, modulates the immune system reducing chronic low-grade inflammation and regulates the microbiota disbalance associated with obesity [25-27].

100 Actually, clinical studies have confirmed that acupuncture treatment for anxiety is 101 effective and has unique advantages [28-30]. Animal experiments have also 102 demonstrated that acupuncture can adjust emotions by regulating the microbiota-gut-103 brain axis, receptors in related regions and signal pathways [31,32]. Intestinal 104 microbiota may be a common mediator connecting obesity and emotions [33,34]. 105 Neuroimaging results show that EA treatment increases ALFF and RSFC in regions 106 like prefrontal cortex (PFC) involved in inhibition control, motivation, sensory and 107 emotional processing in overweight/obesity individuals [35]. Weight gain can 108 negatively impact long-term mental health, which providing a suitable opportunity for 109 acupuncture treatment. Nevertheless, we could not find data to confirm acupuncture's 110 utility for anxiety in overweight/obese people. Moreover, the brain remains a hotbed 111 for research identifying the nuts and bolts of the molecular machinery leading to these 112 profound changes in emotion and body weight. Thus, further explorations need to be 113 conducted to clarify the central mechanism of anxiety with obese patients as well as 114 the mechanism of acupuncture treatment.

## Methods and analysis

- 116 The randomized, blinded, sham- controlled trial aims to evaluate the efficacy and
- safety of electroacupuncture for obese patients with anxiety, including the central
- mechanism of electroacupuncture treatment based on fMRI.

#### Study design

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

115

- 120 This study is a prospective, randomized, participant and assessor blinded, sham-
- controlled, two-armed, parallel-group study with a sample of 72 patients, 36 patients
- in each arm. 72 potential participants from 2 hospitals in Anhui province will be
- recruited through advertising posters from outpatient department of endocrinology,
- department of acupuncture. Patients may also be referred to the trial by their doctors
- 125 (general practitioners, physiotherapists or acupuncturists) and randomly divided into
- 126 EA group and control group in 1:1 ratio by using a computer-generated random
- number table, respectively, 20 patients will be selected from each group before
- treatment. 20 paired healthy participants will be recruited at the same time. The
- results of brain fMRI scanning will be compared to trace the location of specific

- dysfunctional brain regions. Data for the assessment will be collected at baseline, 8-
- 131 week treatment, and one-month follow-up in two groups of patients, and data in
- healthy group will be collected only at baseline.
- 133 This study protocol is reported in line with the Standard Protocol Items
- Recommendations for Interventional Trials (SPIRIT) guidelines [36], which is
- supplied in Supplementary File 1. This trail follows the principles of the Declaration
- of Helsinki (Version Edinburgh 2000). This protocol was registered in the Chinese
- 137 Clinical Trail Registry (ChiCTR2400083594) and approved by the Hospital Ethics
- 138 Committee of Second Affiliated Hospital of Anhui University of Chinese Medicine
- 139 (2023-zj-42). Any modification in protocol is not expected unless necessary. Any
- changes in the selection criteria or methodology will be discussed with the entire
- 141 research team and approved by the ethics committees. The trail flowchart is
- summarized in Figure 1 and Table 1.




Figure 1 Flow diagram of study design.

143

## Table 1 Trial Schedule

Item	Screening (-1 week)	Baseline (0 week)	Ttreatment period (8 week)	Follow-up period (12 week)
Informed consent	×			
Demography	×			
Allocation		×		
Intervention				
EA treatment			×	
Sham EA treatment			×	
Diet diary			×	
Assessment				
Body weight		×	×	×
Waist		×	×	×
BMI		×	×	×
SAS		×	×	×
STAI		×	×	×
PSQI		×	×	×
TC		×	×	
TG		×	×	
FBG		×	×	
Leptin		×	×	
Ghrelin		×	×	

Cortisol		×	×	
ACTH		×	×	
fMRI		×	×	
Participants safety				
Adverse event			×	

- 147 BMI: body mass index; WHR: waist-hip ratio; SAS: Self-rating Anxiety Scale; STAI:
- 148 State-Trait Anxiety Inventory; PSQI: Pittsburgh Sleep Quality Index; TC: total
- cholesterol; TG: triglyceride; FBG: fasting blood glucose; fMRI: functional magnetic
- 150 resonance imaging.

#### 151 Participants

146

- 152 This study will recruit subjects from the Second Affiliated Hospital of Anhui
- 153 University of Chinese Medicine and the Anhui Province Hospital of TCM. Eligibility
- of patients and healthy participants will be assessed by physicians using the criteria
- described below and appropriately compensated after they complete the entire
- 156 procedure. Informed consent will be obtained once eligible patients agree to
- participate in the study.

#### 158 Diagnosis criteria

- 159 This trial will adopt the diagnostic criteria of the World Health Organization for
- obesity in the Asia Pacific region and the diagnostic criteria for overweight/obesity in
- the guidelines for Prevention and Control of overweight and Obesity in Chinese
- Adults formulated by the Ministry of Health of China in 2003:
- 163 1. The body mass index (BMI)≥25kg/m<sup>2</sup>;
- 2. Waist circumference of men ≥85cm, waist circumference of women ≥80cm;
- 165 3. The actual measured body mass exceeds 20% of the standard body mass;
- 166 Note: After excluding secondary causes, it can be diagnosed as simple obesity if the
- above three criteria meet two or more.

#### 168 Inclusion criteria for patients

- 169 1. Patients who meet the diagnostic criteria for simple obesity.
- 170 2. Self-Rating Anxiety Scale (SAS) baseline score ≥ 50 points; State Trait Anxiety
- 171 Inventory (STAI) baseline score ≥ 40 points.
- 172 3. Patients aged 18-45 years.

- 173 4. Patients are right-handed and regardless of gender.
- 5. Patients able to accept the study and sign informed consent.

## 175 Inclusion criteria for healthy participants

- 176 20 age-matched healthy participants with similar age, sex, and educational
- background will be immediately recruited to pair the patients. In addition, healthy
- participants must meet the following criteria: physical fitness (no major illness history,
- 179 no genetic history, no mental, emotional disorders, no acute or chronic disease, no
- 180 cognitive impairment, no brain dysfunction or diseases, etc.), no history of fainting,
- 181 no contraindication for receiving fMRI scanning, and agree to participate in the study
- and complete the treatment and examination as required.

#### 183 Exclusion criteria

- 184 1. Patients with endocrine system disorders and major illnesses that require treatment.
- 185 2. Pregnant or lactating women.
- 186 3. Patients who have participated in acupuncture treatment in the past month.
- 4. Patients who have taken weight loss, anti anxiety and depression related drugs or received weight loss treatment from a nutritionist within the past 3 months.
- 189 5. Patients with contraindications for fMRI.
- 190 6. Patients who are afraid of acupuncture and cannot cooperate with the treatment.

### 191 Drop out criteria

- 192 1. Patients experience severe adverse reactions during the study.
- 2. Patients whose acupuncture treatment is interrupted for one week or more.
- 194 3. The dietary records are largely missing or incomplete.

## 195 Randomization and blinding

- 196 Randomization will be done by SPSS (version 22.0) software in the study. The list of
- 197 generated random numbers will be printed, divided into small pieces, separated and
- sealed in sequentially numbered envelopes. The special screeners will preserve the
- 199 envelopes, and they will open the envelope when each participant is included so the
- group information can be gathered.
- This is a patient-assessor blinded sham-controlled clinical trail. The participants will
- be blinded by using Prak's non-invasive acupuncture needle (Acuprime, the United
- 203 Kingdom) at the same acupoint in the same stimulation manner. Only the traditional
- 204 Chinese medicine (TCM) practitioners know the allocation of each patient. The
- 205 assessors and the data analyst will be blinded to the procedure and results of
- randomization, group allocation, and intervention. After the treatment, the participants
- 207 will be asked about perceived treatment allocation to evaluate the successful rate of
- 208 blinding.

#### 209 Interventions


- 210 The baseline period is one week, the treatment period is eight weeks and the follow-
- 211 up is a month. Weight, waist circumference, BMI, SAS score, STAI score, PSQI
- score will be recorded before, after 8-week treatments and at one-month follow-up in
- 213 patients. In addition, metabolic parameters such as triglyceride (TG), total cholesterol
- 214 (TC), glucose will also be detected before and after 8-week intervention. The dietary
- 215 records are also maintained during EA intervention. The participants in different
- groups will be treated separately to avoid contamination during the process. fMRI will
- be performed in two groups of patients at baseline (week 0), eight weeks after the
- 218 treatment. Healthy participants only receive fMRI scanning at baseline. After the
- 219 follow-up period, the control group will receive an eight-weeks EA treatment as
- 220 compensation.

## 221 EA group

- 222 Acupuncture will be performed by acupuncturists with over 5 years of clinical
- acupuncture experience and obtained a license from the Ministry of Health of the
- 224 People's Republic of China. Before performing the treatment, acupuncturists will
- 225 receive centralized training courses which include an introduction to the basic clinical
- 226 research methods and a practical demonstration of the treatment. Patients will receive
- 227 electroacupuncture treatment three times a week, a total of 24 times for 8 weeks. The
- needle retention time is 30 min at each time.

## 229 Acupuncture acupoints

- 230 The acupuncture point regimen is based on evidence-based clinical practice guidelines
- 231 of traditional Chinese medicine. All acupoints selected and their locations are
- displayed in Figure 2 and Table 2.



**Figure 2** Diagram of acupoints.

## 235 Table 2 Location of acupoints

Acupoints	Location
GV20(Baihui)	On the head, 5 cun above the center of the front hairline
GV24(Shenting )	On the head, 0.5 cun above the center of the front hairline
GV29 (Yintang)	In the depression between the inner ends of the eyebrows on the head
CV12(Zhongw	In the abdomen, 4 cun above the navel, on the anterior midline
an) CV6 (Qihai)	In the lower abdomen, 1.5 cun below the navel, on the anterior midline
	In the lower abdomen, 3 cun below the navel, on the anterior midline

CV4 (Guanyuan)	
ST25 (Tianshu)	In the abdomen, align the navel horizontally , 2 cun next to the anterior midline $% \left( 1\right) =\left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right) \left( 1\right) \left( 1\right) +\left( 1\right) \left( $
SP15 (Daheng)	In the abdomen, align the navel horizontally, 4 cun next to the anterior midline
HT7 (Shenmen)	In the anterior wrist area, at the distal end of the transverse stripe on the palmar side of the wrist, at the radial edge of the tendon in the ulnar wrist area
ST36 (Zusanli)	On the outer side of the calf, 3 cun below the acupoint Dubi, 1 transverse finger outside the anterior tibial crest, on the line connecting the acupoint Dubi and acupoint Jiexi
ST40 (Fenglong)	On the outer side of the calf, 8 cun above the tip of the outer ankle, on the outer edge of the anterior tibial muscle, one finger away from the acupoint Tiaokou
SP6 (Sanyinjiao)	On the inner side of the calf, 3 cun above the tip of the inner ankle, at the posterior edge of the medial edge of the tibia
(Surryminus)	On the anterior depression at the junction of the first and second metatarsals on the dorsum of the foot
LR3 (Taichong)	

#### Manipulation

Patients are in a supine position and the acupoints and needle are disinfected before acupuncture operation. For GV20 (Baihui), the needle will be inserted backward under the cap membrane at angle of 45° with the scalp; for GV24 (Shenting), the needle will be inserted backward under the cap membrane at an angle of 15° with the scalp; for GV29 (Yin tang), the needle will be inserted downward at an angle of 15° under the periosteum; making the patients feel heavy pressure and acid distension. For CV12 (Zhong wan), CV6 (Qihai), CV4 (Guan yuan), ST25 (Tianshu), SP15 (Daheng), HT7 (Shenmen), ST36 (Zusan i), ST40 (Feng long), SP6 (Sanyinjiao) and LR3 (Taichong), needles will be inserted at a depth of 25-35 mm vertically. The needles will be gently rotated and lifted once to achieve a sense of sourness, distention and heaviness. Electroacupuncture will then be applied to the abdominal

- and crural acupoints with 2/10Hz dilatational waves through electronic needle therapy
- 250 device (SDZ-III, Huatuo, China).
- 251 Control group
- 252 Park's non-invasive acupuncture needle will be performed at the same acupoints in
- 253 the same stimulation manner but the needles will only adhere to the skin and nit be
- 254 inserted. The validity and credibility of the model have been fully proven. The
- acupoints in the control group will also be connected to the same electronic needle
- therapy device without electric current.
- 257 Healthy group
- 258 There will be no treatment specifically designed for the healthy group.
- 259 Lifestyle intervention
- 260 Dining according to the guidance of the Chinese Dietary Pagoda. All patients will be
- 261 advised to take regular number of meals daily and not to intake any snacks. In
- 262 addition, all participants will be required not to take exercise except for essential
- activities in their daily work in order to evaluate the sole effect of acupuncture
- treatment. The patient diet diary is supplied in Supplementary File 2.

## **Outcome Measures**

- 266 A printed or electronic case report form (CRF) with the random number for each
- participant will be used to record all information. Two assessors who are blind to the
- 268 group allocations will collect the basic information and assess the outcomes from the
- baseline to the end of follow-up. Telephone interviews combined with offline visits
- are the main methods to use during the follow-up period.

#### 271 Primary outcome measures

- The primary outcomes will be the changes in the weight and SAS scores before and
- after the treatment.
- 274 Self-rating Anxiety Scale (SAS) Self-rating Anxiety Scale (SAS) has been proposed as a
- 275 useful tool for measuring the frequency of anxiety symptoms. The questionnaire
- adopts a four-level rating system with 20 items. Add up the scores of 20 items to
- obtain a rough score and multiply the rough score by 1.25 to obtain the standard score.
- A standard score greater than 50 indicates the presence of anxiety.

### 279 Secondary outcome measures

- 280 The secondary outcomes will include the changes in waist circumference, BMI, STAI
- scores, PSQI score during treatment and follow-up period. Total cholesterol (TC),
- 282 triglyceride (TG), fasting blood glucose (FBG), cortisol, adrenocorticotropic hormone
- 283 (ACTH), leptin and ghrelin will be measured before and after the 8-week treatment.
- Body weight, BMI and WHR are measured by body composition analyzer ( JAWON
- 285 GAIA KIKO, Korea).
- 286 State-trait anxiety inventory (STAI) The State-trait anxiety inventory (STAI) consists of
- 40 questions and is divided into two sub scales, evaluating anxiety as a transient state

- 288 (state anxiety) and a latent trait (trait anxiety). The subscale score ranges from 20 to
- 289 80, with higher scores indicating higher levels of anxiety. [37,38]
- 290 Pittsburgh Sleep Quality Index (PSQI) The 18-item PSQI questionnaire is a reliable and
- valid measure of sleep quality. The total score ranges from 0 to 21. PSQI > 7 as a
- reference threshold for adult sleep quality issues.

#### 293 rs-fMRI examination and data analysis

- A blood oxygenation level dependent gradient echo-planner imaging (BOLD GRE-
- EPI) sequence will be used to scan the whole brain, TR/TE=2000ms/30ms, turning
- angle = 90°, FOV= 220mm ×220mm, matrix = 64×64, slice thickness/spacing=
- 297 3.0/1.0 mm, layer number = 36, scanning time 8 min. All participants will lie flat on
- the scanning bed with their eyes closed, and without performing any tasks.
- 299 Image preprocessing will be conducted by Statistical Parametric Mapping (SPM12,
- 300 http://www.fil.ion.ucl.ac.uk/spm) and the Resting-State fMRI Data Analysis Toolkit
- 301 (REST, http://www.restfmri.net) on Matlab (MathWorks, Inc., Natick, MA, USA).
- Data preprocessing will be accomplished by SPM12: 1) remove the previous 5
- unstable time points of the data; 2) time correction of the remaining time points; 3)
- spatial head motion correction; 4) all the subjects' images will be spatially
- standardized, and re-sampled to a voxel size of  $3 \times 3 \times 3$  mm<sup>2</sup>; 5) remove linear drift;
- 306 6) removal of the covariates of head motion parameters and cerebrospinal fluid signal
- covariates; 7) remove the effects of high-frequency noise by band-pass filtering (0.01-
- 308 0.08 Hz) [39-43].
- 309 The regional homogeneity (ReHo) calculation ReHo measuring the short-distance
- 310 functional connectivity at voxel-level with Kendall's coefficient of concordance
- 311 (KCC), which was calculated from the consistency of the time series between each
- 312 individual hormone and its 26 closest neighbors in the brain region. By calculating the
- 313 KCC value of each given Voxel, the KCC diagram or ReHo diagram of each subject
- 314 can be obtained. ReHo will be obtained by dividing the average KCC value of the
- 315 whole brain into the KCC value of each voxel. Finally, we will smooth with a
- 316 Gaussian kernel of 6 mm full-width at half-maximum (FWHM) to reduce noise [44-
- 317 46].
- 318 The amplitude of low-frequency fluctuation (ALFF) calculation The ALFF algorithm
- 319 assumed that the low frequency BOLD signals in resting-state brain has its
- 320 physiological signification. It uses the average of the amplitudes of all the frequencies
- 321 in a certain frequency band  $(0.01 \sim 0.08 \text{ Hz})$  to characterize the spontaneous activity
- of a voxel which reflects the level of the spontaneous activity of each voxel at rest on
- 323 the view of energy point. The preprocessed time series will be first converted to a
- 324 frequency domain with a fast Fourier transform and the power spectrum is obtained.
- 325 The square root of the power spectrum is computed at each voxel and the averaged
- 326 square root is obtained in the 0.01-0.08 Hz bandwidth at each voxel. For
- 327 standardization, ALFF of each voxel is further divided by whole-brain mean ALFF
- 328 values [47,48].
- 329 The functional connectivity (FC) calculation The regions showing significant results in
- the ALFF are defined as regions-of-interest (ROIs). After obtaining ALFF-ROIs with
- 331 significant main/interaction effects, a seed-region-based (center at coordinates of the

- peak value with a 6mm radius) RSFC-analysis is carried out. We will use band-pass
- filtering with a frequency range of 0.01–0.08 Hz for the RSFC calculation. Meantime-
- series of each ROI from the resting-state-scan is extracted, and then the strength of the
- 335 RSFC for each voxel is estimated using a Pearson-correlation-coefficient between the
- average time-varying signal in the seed and voxel in the brain. Fisher transform is
- used to convert correlation maps into normally distributed coefficient maps. A two-
- 338 way-ANOVA was implemented in SPM 12 to model the effects of group and time on
- seed-based-RSFC with an identical threshold as for ROI identification (pFWE < 0.05,
- 340 cluster size of 50, cluster-forming threshold of p < 0.001). One-sample-t-test is used
- to test the significance of functional connections of each group of ROIs [49].

### **Incidence of Adverse Events**

- 343 EA is widely accepted as relatively safe if applied appropriately by competent
- practitioners. The type, time of occurrence, severity, and duration of the adverse
- events will be recorded in detail from week 0 to 8 and follow-up. Adverse events
- associated with EA might include fainting, stuck needle, bent needle, broken needle
- and hematoma, which will be reported to the Ethics Committee. The determination to
- 348 discontinue the trial for a participant will be made by physicians.
- Participants who suffer harm will be compensated.

## 350 Sample Size

342

- 351 This study estimated the sample size using the sample size estimation formula based
- on the comparison of two sample means described in the following formula:

$$n_1 = n_2 = 2 \left[ \frac{\left( u_{\alpha/2} + u_{\beta} \right)}{\delta/\sigma} \right]^2 + \frac{1}{4} u_{\alpha/2}^2$$

- 353 . Among the formula,  $n_1$  and  $n_2$  are the required
- sample sizes for two groups, respectively. Based on our pre-experiment,  $\delta/\sigma = 0.86$ . In
- this study  $\mu_{\alpha/2}=1.960$ ,  $\mu_{\beta}=1.282$ , after substituting into the above formula, each group
- requires 30 participants. Considering issues such as compliance and loss of follow-up
- during clinical trials, an additional 20% sample size was added, resulting in a total of
- 358 72 participants recruited.

#### Quality Control

- 360 All staff will undergo special training on the purpose and content of the trial,
- 361 treatment strategies, and quality requirements before the trail. Monitors will check the
- participant adverse event table, the participants' dietary diaries and case report form
- once a week as well as the EA operation during the treatment period. Dropouts and
- 364 withdrawals and the underlying reasons will be documented in detail throughout the
- 365 trial.

359

366

#### **Data Collection and Management**

- 367 The researchers will be required to fill the CRF with the data collected in accordance
- 368 with the requirements of the study program. The researchers will submit to data
- management center the complete and signed CRF of all the selected patients in the
- 370 study after the study is finished. The consistency of case report data collected from
- 371 the study will be checked, and queries for inconsistent data will be sent to doctors for

- 372 clarification. The personal CRF of each participant will be stored in a locked cabinet.
- 373 All electronic documents will be stored in Anhui University of Chinese Medicine
- 374 computer with password protection. Access to all research data will only be permitted
- 375 to an authorized research team member.
- 376 All participants will receive a summary of study findings and group information upon
- trial completion. Five years after the end of the project, the electronic documents need
- 378 to be deleted.

379

## Statistical Analysis

- 380 Based on the intention-to-treat (ITT) principle, an independent statistician will verify
- the effectiveness and safety of the intervention. Values missing from the dataset will
- be imputed using last-observation-carried-forward method.
- The statistician will perform statistical analysis by using SPSS 23.0 statistics software
- 384 (SPSS Inc, Chicago, IL, USA) and GraphPad 7.04 statistics software (GraphPad
- 385 Software Co., San Diego, California, USA). For continuous data, the data will be
- presented as mean  $\pm$  SD if normally distributed or as median (IQR) if not normally
- distributed. Longitudinal continuous data will be compared between the groups by
- repeated-measures analysis of variance (ANOVA). Other continuous data will be
- analyzed by Student's t-test and Wilcoxon rank-sum test, and categorical data by X<sup>2</sup>
- 390 test or Fisher's exact test, as appropriate. Linear correlation analysis will be conducted
- 391 to measure the closeness of linear correlation between variables.  $P \le 0.05$  will be
- 392 considered statistically significant.
- 393 For ReHo analysis and ALFF analysis, 2-sample-t-tests will be conducted within the
- anxiety combined with obesity patients and healthy participation before treatment, as
- 395 well as EA group and control group before and after treatment. Paired t-tests will be
- 396 performed between two groups of patients before and after treatment to evaluate the
- ReHo and ALFF difference,  $P \le 0.05$  is used to indicate a significant difference. The
- 398 ALFF brain region (different brain region) to which the peak point belonged will be
- determined according to REST 1.8 software. The different brain regions of the two
- 400 groups will be set as seed points, and the FC between each seed point and other brain
- 401 regions are analyzed separately.

#### 402 **Dissemination**

- The results will be published in peer-reviewed journal, a PhD thesis and presented at
- 404 conferences. Data will be published in aggregate to avoid individual participant
- identification and presented in such a way that identifiable data are removed.

#### Article Summary

- 407 Strengths and limitations of this study This study may provide high-quality
- 408 evidence regarding the efficacy and safety of EA for patients with obesity and anxiety
- 409 comorbidities. In addition, fMRI will be introduced into clinical trials of EA
- 410 intervention and provide further objective basis for the efficacy, immediate effect,
- 411 cumulative effect and long-term effect of EA treatment. However, the current trail has
- 412 a small sample size.

#### Trial Status

- Participant enrollment is started from May 2024. 40 participants have been recruited
- 415 till now.

413

#### 416 Abbreviations

- 417 EA: Electroacupuncture; rs-fMRI: resting-state functional magnetic resonance
- 418 imaging; BMI: Body mass index; SAS: Self-rating anxiety scale; STAI: State-trait
- anxiety inventory; PSQI: Pittsburgh sleep quality index; TG: Triglyceride; TC: Total
- 420 cholesterol; FBG: Fasting blood glucose; ReHo: Regional homogeneity; ALFF:
- 421 Amplitude of low-frequency fluctuation; RSFC: Resting-state-functional-connectivity;
- 422 SPIRT: Standard Protocol Items Recommendations for Interventional Trials; TCM:
- 423 Traditional Chinese medicine; CRF: case report form; ITT: Intention-to-treat; HPA:
- 424 Hypothalamic-pituitary-adrenal; RCT: Randomized controlled trial; PFC: prefrontal
- 425 cortex.

## 426 Acknowledgements

We appreciate the effort and help from all of those involved in this trial.

#### 428 **Author Contributions**

- 429 QS is the main researcher who designed the study, drafted the manuscript and
- registered the trail in Chinese Clinical Trail Registry. QMP is the co-researcher who
- 431 contributed to the design of the protocol and writing of the manuscript. WXD and
- 432 FZ contributed to the design of the interventions. QY contributed to the statistical
- design and the revision of the manuscript. RLC provided the funding and revised the
- manuscript. All authors contributed to the revision and approved the final manuscript.

#### 435 **Funding**

- 436 This work is supported by the "Unveiled and Leading" Project (2023CXMMTCM019)
- 437 from the Center for Xin'an Medicine and Modernization of Traditional Chinese
- 438 Medicine, Insitute of Health and Medicine, Hefei Comprehensive National Science
- 439 Center. The funding organization has no role in designing and analyzing the study.

#### 440 Availability of data and materials

- No data were used to support this protocol. The outcomes data of the trial will be
- 442 published within the final study manuscript and will also be uploaded to the Chinese
- 443 Clinical Trial Registry.

#### 444 **Declarations**

#### 445 Ethics approval and consent to participate

- 446 This study has been approved by the Ethics Committee of the Second Affiliated
- 447 Hospital of Anhui University of Chinese Medicine (Approved number: 2023-zj-42).
- All participants will be informed and sign a written consent form.

#### 449 Patient and public involvement

- 450 Patients and/or the public were involved in the design, or conduct, or reporting, or
- dissemination plans of this research. Refer to the Methods section for further details.
- 452 Patient consent for publication
- 453 Not applicable.
- 454 Provenance and peer review
- Not commissioned; externally peer reviewed.
- 456 Competing interests
- The authors declare that they have no competing interests.
- 458 References
- 459 [1] Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity:
- epidemiology and health consequences. Lancet Diabetes Endocrinol. 2016,4:1025–1036.
- 461 [2] Raman J, Smith E, Hay P. The clinical obesity maintenance model: An integration of
- 462 psychological constructs including mood, emotional regulation, disordered overeating, habitual
- cluster behaviours, health literacy and cognitive function. J Obes. 2013,2013:1–9.
- 464 [3] Endalifer ML, Diress G. Epidemiology, predisposing factors, biomarkers, and prevention
- mechanism of obesity: a systematic review. J Obes. 2020;2020: 6134362
- 466 [4] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes
- 467 Endocrinol. 2021;9(6):373–92.
- 468 [5] Susan L. McElroy, Renu Kotwal, Shishuka Malhotra, et al. Are mood disorders and obesity
- related? A review for the mental health professional. J Clin Psychiatry. 2004,65:634-651.
- 470 [6] Rajan, T. M., & Menon, V. Psychiatric disorders and obesity: A review of association studies.
- 471 Journal of Postgraduate Medicine. 2017,63(3), 182–190.
- 472 [7] Gibson EL. The psychobiology of comfort eating: implications for neuropharmacological
- 473 interventions. Behav Pharmacol. 2012,23:442–60.
- 474 [8] Irene Svenningsson, Cecilia Bjorkelund, Bertil Marklund, et al. Anxiety and depression in
- obese and normal-weight individuals with diabetes type 2: a gender perspective. Scandinavian
- 476 Journal of Caring Sciences. 2012,26:349-354.
- 477 [9] Kauffman, B. Y., Garey, L., Jardin, C., et al. Body mass index and functional impairment: The
- 478 explanatory role of anxiety sensitivity among treatment-seeking smokers. Psychology, Health &
- 479 Medicine. 2018, 23(2), 232–243.
- 480 [10] Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the
- population: a systematic review and meta-analysis. Int J Obes. 2010,34(3):407–419.
- 482 [11] Clemence Willem, Marie-Charlotte Gandolphe, Karyn Doba, et al. Eating in case of emotion
- 483 dys-regulation, depression and anxiety: Different pathways to emotional eating in moderate and
- severe obesity. Clinical Obesity. 2020:e12388.
- 485 [12] van Strien T, Donker MH, Ouwens MA. Is desire to eat in response to positive emotions an
- 486 "obese" eating style: is Kummerspeck for some people a misnomer? Appetite. 2016;100:225-235.
- 487 [13] Ouakinin SR, Barreira DP, Gois CJ. Depression and obesity: Integrating the role of stress,
- 488 neuroendocrine dysfunction and inflammatory pathways. Front Endocrinol. 2018, 9:431.

- 489 [14] N.R.W.Geiker, A. Astrup, M. F. Hjorth, et al. Does stress influence sleep patterns, food
- 490 intake, weight gain, abdominal obesity and weight loss interventions and vice versa? Obes Rev.
- **491** 2018,19(1):81-97.
- 492 [15] Sinha R, Jastreboff AM. Stress as a common risk factor for obesity and addiction. Biol
- 493 Psychiatry. 2013; 73: 827–835.
- 494 [16] S-Y Kim, I-S Shin and Y-J Park. Effect of acupuncture and intervention types on weight loss:
- a systematic review and meta-analysis. Obesity Reviews. 2018,19(11):1585-1596.
- 496 [17] Linda L. D. Zhong, Xingyao Wu, Tsz Fung Lam, et al. Electro-acupuncture for central
- 497 obesity: randomized, patient-assessoe blinded, sham-controlled clinical trial protocol. BMC
- 498 Complementary Medicine Therapie. 2021,21:190.
- 499 [18] Cho SH, Lee JS, Thabane L, et al. Acupuncture for obesity: a systematic review and meta-
- analysis. Int J Obes.2009,33(2):183-96.
- 501 [19] Yin Y, Zhao Q, Li S, et al. Efficacy of acupuncture and moxibustion therapy for simple
- obesity in adults: a meta-analysis of randomized control trials. Medicine,2022,101(43):e31148.
- 503 [20] Huang D, Liu Z, Xu B, et al. Effect of acupuncture and moxibustion on severe obesity
- complicated with hyperlipidemia in different genders. Zhongguo Zhen Jiu, 2018, 38(7):685-689.
- 505 [21] Wang L, Yu CC, Li J, et al. Mechanism of action of acupuncture in obesity: a perspective
- from the hypothalamus. Front Endocrinol. 2021,12:632324.
- 507 [22] Jason Aaron Chen, Justin Albert Chen, Sanghoon Lee, et al. Potential role for acupuncture in
- the treatment of food addiction and obesity. Acupunct Med. 2017,0:1-4.
- 509 [23] Fang S, Wang M, Zheng Y, et al. Acupuncture and lifestyle modification treatment for
- obesity: a meta-analysis. Am J Chin Med. 2017,45(2):239-254.
- 511 [24] Kim SY, Shin IS, Park YJ. Comparative effectiveness of a low-calorie diet combined with
- 512 acupuncture, cognitive behavioral therapy, meal replacements, or exercise for obesity over
- 513 different intervention periods: a systematic review and network meta-analysis. Front Endocrinol.
- **514** 2022,13:772478.
- 515 [25] Park KS, Park KI, Suh HS, Hwang DS, Jang JB, Lee JM. The efficacy and safety of
- acupuncture on serum leptin levels in obese patients: A systematic review and metaanalysis. Eur J
- 517 Integr Med. 2017, 11:45–52.
- 518 [26] Sheng J, Yang G, Jin X, Si C, Huang Y, Luo Z, et al Electroacupuncture combined with diet
- 519 treatment has a therapeutic effect on perimenopausal patients with abdominal obesity by
- improving the community structure of intestinal flora. Front Physiol. 2021, 12:708588.
- 521 [27] Raymond Guy Landgraaf, Michelle Nicte Bloem, Massimo Fumagalli, et al. Acupuncture as
- multitargeted therapy for the multifactorial disease obesity: a complex neuro-endocrine-immune
- 523 interplay. Front. Endocrinol. 2023,14:1236370.
- 524 [28] Fan JQ, Lu WJ, Tan WQ, et al. Effectiveness of acupuncture for anxiety among patients with
- parkinson disease: a randomized clinical trial. JAMA Netw Open. 2022,5(9):e2232133.
- 526 [29] Amorim D, Brito I, Caseiro A, et al. Electroacupuncture and acupuncture in the treatment of
- 527 anxiety-a double blinded randomized parallel clinical trail. Complement Ther Clin Pract.
- **528** 2022,46:101541.
- 529 [30] Zanella S, Buccelletti F, Vassiliadis A, et al. Preoperative anxiety management: acypuncture
- vs. pharmacological treatment-a prospective study. Eur Rev Med Pharmacol Sci. 2022,26(3):900-
- **531** 905.

- 532 [31] Bai L, Zhang D, Cui TT, et al. Mechanisms underlying the antidepressant effect of
- acupuncture via the CaMK sihnaling pathway. Front Behav Neurosci. 2020,14:563698.
- 534 [32] Wu M, Chen Y, Shen Z, et al. Electroacupuncture alleviates anxiety-like behaviors induced
- by chronic neuropathic pain regulating different dopamine receptors of the basolateral amygdala.
- 536 Mol Neurobiol. 2022,59(9):5299-5311.
- 537 [33] Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev.
- **538** 2019,99(4):1877-2013.
- 539 [34] Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiota-brain axis and its effect on
- neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015,37(5):984-995.
- 541 [35] Yuanyun Ren, Mingzhu Xu, Karen M. von Deneen, et al. Acute and long-term effects of
- 542 electroacupuncture alter frontal and insular cortex activity and functional connectivity during
- resting state. Psychiatry Research: Neuroimaging. 2020; 298:111047.
- 544 [36] Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K,
- 545 Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013
- Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586
- 547 [37] Spielberger CD, Gorsuch RC, Lushene RE. Manual for the StateTrait Anxiety Inventory. Palo
- Alto, CA: Consulting Psychologists Press; 1970.
- 549 [38] Iknur Yeşilçınar, Gamze Acavut, Gülten Güvenç. Anxiety during the pregnancy and affecting
- factors: a cross-sectional study. Archives of Gynecology and Obstetrics, 2023,307(1):301-309.
- 551 [39] Tsai YH, Yuan R, Patel D, et al Altered structure and functional connection in patients with
- classical trigeminal neuralgia. Hum Brain Mapp. 2018;39(2):609–621.
- 553 [40] Long X, Liu F, Huang N, et al Brain regional homogeneity and function connectivity in
- 554 attenuated psychosis syndrome -based on a resting state fMRI study. BMC Psychiatry.
- **555** 2018;18(1):383.
- 556 [41] Sun J, Li R, Li X, et al Electroacupuncture therapy for change of pain in classical trigeminal
- neuralgia. Medicine. 2020;99(16):e19710.
- 558 [42] Chunlin Li, Yuangeng Wang, Baopeng Li, et al. Effects of acupuncture at neiguan in neural
- activity of related brain regions: a resting-state fMRI study in anxiety. Neuropsychiatric Disease
- 560 and Treatment. 2022,18:1375-1384.
- 561 [43] Yang He, Karen M. von Deneen, Guanya Li, et al. Electroacupuncture enhances resting-state
- functional connectivity between dorsal caudate and precuneus and decreases associated leptin
- levels in overweight/obese subjects. Brain Imaging and Brhavior. 2022,16:445-454.
- [44] Xiang CQ, Liu WF, Xu QH, et al Altered spontaneous brain activity in patients with classical
- trigeminal neuralgia using regional homogeneity: a resting-state functional MRI study. Pain Pract.
- **566** 2019;19 (4):397–406.
- 567 [45] Ding Tang, Xufen Zhang, Yani Xu, et al. The central response of electroacupuncture on
- trigeminal neuralgia based on resting-state functional magnetic resonance imaging: a protocol for
- a pre-experimental, single-centre, randomized, controlled trail. Journal of Pain Research.
- **570** 2021,14:3321-3331.
- 571 [46] Yue Ma, Zhi Wang, Jiakai He, et al. Transcutaneous auricular vagus nerve immediate
- 572 stimulation treatment for treatment-resistant depression: a functional magnetic resonance imaging
- **573** study. Frontiers in Neurology.2022,13:931838.
- 574 [47] Yuangeng Wang, Chunlin Li, Xianghua Qi. The effect of acupuncture at the Yuji point on
- resting=state brain function in anxiety. Medicine. 2023,102(8):e33094.

- 576 [48] Yukai Wang, Tie Li, Lijuan Ha, et al. Effectiveness and cerebral responses of multi-points
- acupuncture for primary insomnia: a preliminary randomized clinical trail and fMRI study. BMC
- 578 Complementary Medicine and Therapies. 2020,20:254.
- 579 [49] Xingxian Huang, Yuanyuan Zhou, Xinru Wang, et al. Structual and functional improvement
- 580 of amygdala sub-regions in postpartum depression after acupuncture. Fronteries in Human
- 581 Neuroscience. 2023,17:1163746.

# Reporting checklist for protocol of a clinical trial.

584 Based on the SPIRIT guidelines.

## Instructions to authors

- 586 Complete this checklist by entering the page numbers from your manuscript where
- readers will find each of the items listed below.
- 588 Your article may not currently address all the items on the checklist. Please modify
- your text to include the missing information. If you are certain that an item does not
- 590 apply, please write "n/a" and provide a short explanation.
- 591 Upload your completed checklist as an extra file when you submit to a journal.
- 592 In your methods section, say that you used the SPIRITreporting guidelines, and cite
- 593 them as:

582

583

585

- 594 Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K,
- Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D.
- 596 SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials.
- 597 BMJ. 2013;346:e7586

Page Number

#### **Administrative** information Title <u>#1</u> Descriptive title identifying 1 the study design, population, interventions, and, if applicable, trial acronym #2a 2, line 48 Trial registration Trial identifier and registry name. If not yet registered, name of intended registry Trial registration: #2b All items from the World 2 data set Health Organization Trial Registration Data Set

Protocol version	<u>#3</u>	Date and version identifier	n/a
Funding	<u>#4</u>	Sources and types of financial, material, and other support	15
Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	15
Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	n/a
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	13-14
Introduction			
Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	2-3
Background and rationale: choice	<u>#6b</u>	Explanation for choice of comparators	2

of comparators Objectives #7 Specific objectives or 3,line 114-116 hypotheses Trial design <u>#8</u> Description of trial design 3-6 including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) Methods: Participants, interventions, and outcomes Study setting <u>#9</u> Description of study 4-6 settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained Eligibility criteria **#10** Inclusion and exclusion 6-7 criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) Interventions: **#11a** Interventions for each 8-11 description group with sufficient detail to allow replication, including how and when they will be administered Interventions: #11b Criteria for discontinuing or 7 modifications modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease) Interventions: #11c Strategies to improve n/a adherance adherence to intervention protocols, and any

		procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	11-13
Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	5, figure 1
Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	3
Methods: Assignment of interventions (for controlled			

#### trials)

and analysis

Allocation: #16a Method of generating the 8 sequence allocation sequence (eg, generation computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions Allocation #16b Mechanism of 8 concealment implementing the allocation mechanism sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned Allocation: #16c Who will generate the 6 and 8 implementation allocation sequence, who will enrol participants, and who will assign participants to interventions Blinding #17a Who will be blinded after 8 assignment to interventions (masking) (eg, trial participants, care providers, outcome assessors, data analysts), and how Blinding #17b If blinded, circumstances n/a (masking): under which unblinding is emergency permissible, and procedure for revealing a participant's unblinding allocated intervention during the trial Methods: Data collection, management,

Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13-14
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13-14
Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14
Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
Statistics: analysis population and	<u>#20c</u>	Definition of analysis population relating to	14

missing data

protocol non-adherence (eq, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

## Methods: Monitoring

Data monitoring: formal committee

Composition of data #21a monitoring committee

(DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about

its charter can be found, if not in the protocol. Alternatively, an

explanation of why a DMC

is not needed

n/a

There are three reasons that we don't need DCM. Firstly. data collectors, intervention operators and evaluators in our program do not interfere with each other, ensuring that data is not leaked or contaminated. Secondly, all staff will undergo special training on the purpose and content of the trial, treatment strategies, and quality requirements before the trail. Monitors will check the participant adverse event table, the participants' dietary diaries and case report form once a week as well as the EA operation during the treatment period. Lastly, our sample size is too small to support

Data monitoring: interim analysis

Harms

#21b Description of any interim

analyses and stopping quidelines, including who will have access to these interim results and make the final decision to terminate the trial

<u>#22</u>

Plans for collecting, assessing, reporting, and 13

DCM.

13

managing solicited and

		spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	4
Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	4
Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	13-14

Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	16
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	15
Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	8 and 13
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or	n/a

molecular analysis in the current trial and for future use in ancillary studies, if applicable

598	None The SPIRIT Explanation and Elaboration paper is distributed under the terms of
599	the Creative Commons Attribution License CC-BY-NC. This checklist can be
600	completed online using <a href="https://www.goodreports.org/">https://www.goodreports.org/</a> , a tool made by the <a href="EQUATOR">EQUATOR</a>
601	Network in collaboration with Penelope.ai
602	

